Abstract
Hormonal therapy administered before radical prostatectomy to reduce tumour size in patients with prostate cancer is of little value in preventing relapse, and only serves to ‘confuse the pathology’, experts said at the 92nd Annual Meeting of the American Urological Association [New Orleans, US; April 1997]. A multicentre study presented at the meeting confirmed this view. Results of the study showed that men receiving ‘neoadjuvant’ hormonal therapy before surgery for early prostate cancer had recurrence rates virtually identical to men who received no pre-surgical therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
